# Serum Interleukin -21 Level in Patients With Severe Adverse Cutaneous Drug Reaction.

> **NCT03166241** · NA · UNKNOWN · sponsor: **Assiut University** · enrollment: 30 (estimated)

## Conditions studied

- Adverse Cutaneous Reaction to Alternative Medical Therapy

## Interventions

- **DIAGNOSTIC_TEST:** serum interleukin 21
- **DIAGNOSTIC_TEST:** Complete Blood Picture
- **DIAGNOSTIC_TEST:** Liver function test
- **DIAGNOSTIC_TEST:** Random Blood Sugar
- **DIAGNOSTIC_TEST:** Erythrocyte Sedimentation Rate
- **DIAGNOSTIC_TEST:** Kidney function tests

## Key facts

- **NCT ID:** NCT03166241
- **Lead sponsor:** Assiut University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-07
- **Primary completion:** 2018-07
- **Final completion:** 2018-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2017-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03166241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03166241, "Serum Interleukin -21 Level in Patients With Severe Adverse Cutaneous Drug Reaction.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03166241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*